Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Higgins, P. G.
Right arrow Articles by Amyes, S. G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higgins, P. G.
Right arrow Articles by Amyes, S. G. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 71
© 2000 The British Society for Antimicrobial Chemotherapy

Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro

Paul G. Higginsa,*, Kenneth Colemanb and Sebastian G. B. Amyesa

a Department of Medical Microbiology, The Medical School, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK; b SmithKline Beecham Pharmaceuticals, 1250 Collegeville Road, Collegeville, PA 19426, USA

This study compared the in vitro bacteriostatic activity of gemifloxacin (SB-265805) and a panel of test antimicrobial agents against 100 clinical isolates of Acinetobacter spp. (47 Acinetobacter baumannii, 18 Acinetobacter anitratus, 18 Acinetobacter lwoffii, 13 Acinetobacter calcoaceticus and four other Acinetobacter spp.). Gemifloxacin (MIC50/90 0.06/16 mg/L) was more than eight-fold more potent than ciprofloxacin (0.5/>128 mg/L), two- to eight-fold more potent than grepafloxacin, moxifloxacin, levofloxacin, ofloxacin and gatifloxacin, and of similar potency to trovafloxacin and sparfloxacin. Cross-resistance was seen only within the quinolone group and did not extend to non-quinolone antimicrobials. The bactericidal activities of gemifloxacin and the six comparator quinolones were investigated by dose–response and time–kill studies against A. baumannii ATCC 19606 at their optimum bactericidal concentration (OBC) and at 4 x MIC. At the OBC there was no significant difference between the quinolones, but at 4 x MIC gemifloxacin showed superior activity, reducing the viable count by almost 2 log10 in 30 min compared with a 1 log10 reduction seen with the other drugs. This enhanced killing extended over 24 h, reducing cell numbers by >4 log10. These data suggest that gemifloxacin has the potential to be of therapeutic value in the treatment of infection by Acinetobacter spp.

* Corresponding author. Tel: +44-131-6508270; Fax: +44-131-6506882; E-mail: paul.higgins{at}ed.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. Vila, A. Ribera, F. Marco, J. Ruiz, J. Mensa, J. Chaves, G. Hernandez, and M. T. Jimenez De Anta
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates
J. Antimicrob. Chemother., March 1, 2002; 49(3): 471 - 477.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.